FDA Updates Safety Label for Capecitabine and 5 FU for Risks Associated With DPD Deficiency Oncology Nursing Society FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The Pharmacology of Longevity: Peptide Edition (Part 1) FDA Compliance for Peptide Therapy and BPC 157 Holt Law